Given these considerations, we present an observational study that examined in patients with stage I-IV TCC, several clinicopathologic features, including KRAS, BRAF, and MSI, to evaluate any relationship between their expression and clinical outcome. The gene discussed is BRAF; the disease is tarsal-carpal coalition syndrome.